Aristotle University Of Thessaloniki (AUTH)
Ο ρόλος της χορήγησης ερυθροποιητίνης στην αντιμετώπιση της αναιμίας της προωρότητας
Abstract
dc:descriptionRecent advances in neonatal intensive care have remarkably increased survival in very low birth weight neonates (VLBW). However, the development of “anemia of prematurity” (AOP) during hospital stay is of significant clinical concern in these neonates. AOP is a normochromic, normocytic anemia characterized by reticulocytopenia and bone marrow hypoplasia, and is associated with lower than expected for the severity of anemia erythropoietin (EPO) levels. Premature neonates, especially those being seriously ill, undergo loss of a large amount of blood due to various laboratory tests performed within the first weeks after birth. Consequently, frequent blood transfusions are needed in order to correct both iatrogenic and anemia of prematurity. It is well recognized, though, that erythrocyte transfusions entail various risks, such as infections, sensitization to blood group antigens, graft versus host reaction, hypothermia, apnea, hypotension and metabolic disturbances. In addition, they have been linked to an increased risk for Retinopathy of Prematurity (ROP). Multiple transfusions of blood products derived from multiple donors increase the above-mentioned risks. Given that anemia of prematurity is characterized by low levels of EPO and increased numbers of red cell progenitors shown to react with recombinant Human Erythropoietin (rHu-EPO) in vitro, several investigators have examined its role for the prevention and treatment of AOP. However, the results of the relevant clinical studies regarding the effectiveness of rHu-EPO are different and sometimes conflicting, yielding inconclusive conclusions from metanalyses. The first aim of this study was to investigate the effectiveness of early rHu-EPO administration (1st–7th day of age) on VLBW premature neonates (GA≤32 weeks, BW≤1250g) in preventing and treating AOP by its erythropoiesis stimulating action. The second aim of this study was to record any potential adverse effect of rHu-EPO administration and to examine the long-term effects of rHu-EPO treatment on erythropoiesis after drug discontinuation. In addition, we investigated any possible association of the rHu-EPO treatment with early complications of prematurity and long-term neurodevelopmental outcome. To this aim, 129 premature neonates, admitted at the A’ Neonatal Clinic and Neonatal Intensive Care Unit of the Aristotle University of Thessaloniki from 2001 to 2004 were studied. In this prospective controlled study, enrolled neonates were randomly assigned into two groups: the rHu-EPO group (n=67) where rHu-EPO (250IU/kg subcutaneously) was administered within the first 96 hours of life and the control group (n=62). All neonates received oral iron and folic acid supplementation, when 2/3 of their daily needs were administered orally, and up to discharge. Initial iron dose given to the rHu-EPO group was 4mg/kg divided in 2-3 daily doses, and increasing progressively up to 12mg/kg/d. The control group was given iron at a dose of 4mg/kg/d. Neonates were clinically and laboratory followed up. Serial measurements of the hematological parameters, such as Hb, Hct and erythrocytes indices, platelets, reticulocyte and white blood cell counts, biochemical parameters as well as serum levels of ferritin, erythropoietin and sTfR were performed at baseline, every 14 days until discharge and at the 4th 6th and 12th months of life, thereafter. At the same time, the number of transfusions, volume of the transfused blood, frequency of early complications of prematurity (respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, retinopathy of prematurity, sepsis, intra-periventricular hemorrhage), as well as the long term neurodevelopmental outcome were recorded. Data analysis showed that the number of blood transfusions was significantly lower in the rHu-EPO treated infants as compared the control group. The percentage of neonates who did not receive any blood transfusion during the study period was 29,8% for the rHu-EPO group and 12,9% for the control group, respectively. In neonates with GA≤28 weeks, a significantly lower blood volume was transfused in those treated with rHu-EPO as compared to control group, and despite the fact that the quantity of blood drawn for laboratory tests during the study was comparable between groups. This was also the case with a subgroup of neonates subjected to mechanical ventilation of long duration. Blood volume removed for laboratory tests during hospitalization was significantly larger -almost double- in the subgroup of patients with GA≤28 weeks in comparison with those being of greater GA (≥29 weeks). In both groups, soluble transferrin receptor levels (sTfR) were found to be significantly higher at birth than during hospitalization, reflecting intense erythropoietic activity during the third trimester of pregnancy. After the initial decrease observed in both groups, sTfR levels remained significantly higher in the rHu-EPO group during the treatment period, also suggestive of intense erythropoiesis. Ferritin levels in the rHu-EPO group decreased progressively as compared to the control group, indicating a rapid mobilization of iron stores during erythropoiesis. After rHu-EPO discontinuation, no differences in terms of hematocrit, hemoglobin and serum erythropoietin levels were observed at the 4th, 6th and 12th months of age. Regarding the adverse effects of rHu-EPO, no neonate presented with neutropenia, disorders of platelet number or hypertension. Also, none of the studied neonate manifested any vascular dysplasias. The incidence of prematurity associated complications (RDS, BPD, NEC, ROP, sepsis, IVH), was not found to be affected by rHu-EPO administration. Interestingly, the incidence of severe ROP requiring cryo-therapy was lower in the rHu-EPO group, but the difference was not significant. Moreover, intra-periventricular hemorrhage (IVH) of any degree was significantly lower in the rHu-EPO group than in the control group. However, the incidence of severe intraventricular hemorrhage was comparable between groups. Finally, neurodevelopmental outcome at 18-24 months of age did not differ between the two groups. Further analysis according to erythropoietin levels at birth, revealed that high EPO levels were related to a better early neurological outcome. It is possible that increased levels of erythropoietin at birth, due to prolonged intrauterine hypoxia, consists an innate protective mechanisms that prevents subsequent neurological damage. In conclusion, rHu-EPO administration at the dose of 250IU/kg, every other day, starting from the 1st week of life, in neonates with GA≤29 weeks and BW≤1000 g, seems to prevent AOP, which usually appears within the 2nd week of age, but not the iatrogenic anemia observed in VLBW and severely ill neonates. Thus, it is not possible to completely avoid erythrocyte transfusion in low birth weight premature neonates. In addition, rHu-EPO effectively stimulates erythropoiesis, as suggested by the significantly increased reticulocyte counts, hematocrit and hemoglobin levels in treated neonates. However, for successful stimulation of erythropoiesis, along with rHu-EPO administration, iron supplementation is required. Finally, rHu-EPO administration for the treatment of AOP is safe in neonates, as it is neither associated with adverse effects, nor affects the production of the other cell lines in bone marrow or endogenous erythropoiesis after its discontinuation. Also, it does not seem to have any significant impact on the incidence of complications of prematurity. However, rHu-EPO treatment might have a neuroprotective effect, although at the dosage used for its hemopoietic action, its potential neuroprotective properties do not occur. The beneficial effect of rHu-EPO could be enhanced if strict blood sampling and transfusion criteria regarding very low birth weight neonates were applied in NICUs. Erythropoietin, by its multifunctional action, is a promising drug, because besides from its beneficial effect on erythropoiesis, may reduce neonatal morbidity and improve neurodevelopmental outcome of very low birth weight infants.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Pouliou-Deli, Theodora
- Πούλιου-Δελή, Θεοδώρα
Subjects
dc:subject × 18- Αναιμία προωρότητας
- Ερυθροποιητίνη
- Ερυθροποίηση
- Νεογνά, Πολύ χαμηλού βάρους ( ΠΧΒΝ )
- Μεταγγίσεις αίματος
- Νευροαναπτυξιακή εξέλιξη
- Σίδηρος, Χορήγηση
- Anemia of prematurity
- Erythropoietin
- Erythropoiesis
- Neonates, Very low birth weight ( VLBN )
- Blood transfusions
- Neurodevelopmental outcome
- Iron administration
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19527